Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.

Weekly infusions of idursulfase have no tangible benefit in boys with type II mucopolysaccharidosis who already have respiratory involvement, while hypersensitivity reactions are frequent and sometimes serious. Idursulfase should only be given to infants if they are enrolled in clinical trials.

Keywords

Europe, Male, Clinical Trials as Topic, Humans, Iduronate Sulfatase, Child, Drug Approval, Mucopolysaccharidosis II

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average